Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company,
announced today that data on its investigational drug PV-10 will be
featured in a presentation by investigators from Moffitt Cancer Center
in a Poster Highlights Session of the American Society of Clinical
Oncology (ASCO) Annual Meeting at McCormick Place, Chicago, IL, May
30-June 3, 2014. The time and date of the presentation are expected to
become available on the ASCO website, http://am.asco.org,
on April 21, 2014.
The poster, based upon abstract #9028, is entitled "Assessment of immune
and clinical efficacy after intralesional PV-10 in injected and
uninjected metastatic melanoma lesions," and is authored by Amod
Sarnaik, MD and colleagues of Moffitt.
Craig Dees, PhD, CEO of Provectus said, "We value our relationship with
Moffitt greatly, and we are excited by the assessment Dr. Sarnaik has
made on clinical and immunologic activity of intralesional PV-10.”
Provectus has recently submitted an application to the FDA for
breakthrough therapy designation for PV-10 based on the results from its
Phase 2 clinical study of melanoma and is researching its efficacy for
other indications.
About Moffitt Cancer Center
Located in Tampa, Moffitt is one of only 41 National
Cancer Institute-designated Comprehensive Cancer Centers, a
distinction that recognizes Moffitt’s excellence in research, its
contributions to clinical trials, prevention and cancer control. Moffitt
is the No. 1 cancer hospital in Florida and has been listed in U.S. News
& World Report as one of “America’s Best Hospitals” for cancer since
1999. For more information, visit MOFFITT.org,
and follow the Moffitt momentum on Facebook,
Twitter
and YouTube.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology and
dermatology therapies. Its novel oncology drug PV-10 is designed to
selectively target and destroy cancer cells without harming surrounding
healthy tissue, significantly reducing potential for systemic side
effects. Its oncology focus is on melanoma, breast cancer and cancers of
the liver. The Company has received orphan drug designations from the
FDA for its melanoma and hepatocellular carcinoma indications. Its
dermatological drug PH-10 also targets abnormal or diseased cells, with
the current focus on psoriasis and atopic dermatitis. Provectus has
recently completed Phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis and
psoriasis. Information about these and the Company's other clinical
trials can be found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus please visit the Company's
website at www.pvct.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained
herein are subject to certain risks and uncertainties that could cause
actual results to differ materially from those reflected in the
forward-looking statements. Readers are cautioned not to place undue
reliance on these forward-looking statements, which reflect management's
analysis only as of the date hereof. The company undertakes no
obligation to publicly revise these forward-looking statements to
reflect events or circumstances that arise after the date thereof.
Copyright Business Wire 2014